LIVIVO - Search results -

Search results

Result 1 - 10 of total 104

Search options

Article ; Online: Frequency of CXCR3

Tibúrcio, Rafael / Narendran, Gopalan / Barreto-Duarte, Beatriz / Queiroz, Artur T L / Araújo-Pereira, Mariana / Anbalagan, Selvaraj / Nayak, Kaustuv / Ravichandran, Narayanan / Subramani, Rajasekaran / Antonelli, Lis R V / Satagopan, Kumar / Anbalagan, Komathi / Porter, Brian O / Sher, Alan / Swaminathan, Soumya / Sereti, Irini / Andrade, Bruno B

Frontiers in immunology

2022 Volume 13, Page(s) 873985

Abstract: Background: Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is a clinical aggravation of TB symptoms observed among a fraction of HIV coinfected patients shortly after the start of antiretroviral therapy (ART). Of note, TB- ... ...

Abstract	Background: Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is a clinical aggravation of TB symptoms observed among a fraction of HIV coinfected patients shortly after the start of antiretroviral therapy (ART). Of note, TB-IRIS is characterized by exacerbated inflammation and tissue damage that occurs in response to the elevated production of CD4 Methods: We performed a comprehensive assessment of the composition of CD8 Results: We found that TB-IRIS individuals display higher frequencies of Antigen-experienced CD8 Conclusion: Our data suggest that TB-IRIS individuals display a distinct profile of memory CD8
MeSH term(s)	CD8-Positive T-Lymphocytes ; HIV Infections ; Humans ; Immune Reconstitution Inflammatory Syndrome ; Inflammation/complications ; Receptors, CXCR3 ; T-Lymphocyte Subsets ; Tuberculosis
Chemical Substances	CXCR3 protein, human ; Receptors, CXCR3
Language	English
Publishing date	2022-04-01
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Intramural
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2022.873985
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J).

Kishimoto, Mitsumasa / Taniguchi, Atsuo / Fujishige, Ayako / Kaneko, Shuhei / Haemmerle, Sibylle / Porter, Brian O / Kobayashi, Shigeto

Modern rheumatology

2019 Volume 30, Issue 1, Page(s) 132–140

Abstract: Objective: ...

Abstract	Objective:
MeSH term(s)	Adult ; Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Injections, Subcutaneous ; Japan ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Spondylitis, Ankylosing/diagnosis ; Spondylitis, Ankylosing/drug therapy ; Time Factors ; Treatment Outcome
Chemical Substances	Antibodies, Monoclonal, Humanized ; secukinumab (DLG4EML025)
Language	English
Publishing date	2019-01-03
Publishing country	United States
Document type	Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
ZDB-ID	2078157-X
ISSN	1439-7609 ; 1439-7595
ISSN (online)	1439-7609
ISSN	1439-7595
DOI	10.1080/14397595.2018.1538004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2982: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Spatially consistent microbial biomass and future cellular carbon release from melting Northern Hemisphere glacier surfaces

Ian T. Stevens / Tristram D. L. Irvine-Fynn / Arwyn Edwards / Andrew C. Mitchell / Joseph M. Cook / Philip R. Porter / Tom O. Holt / Matthias Huss / Xavier Fettweis / Brian J. Moorman / Birgit Sattler / Andy J. Hodson

Communications Earth & Environment, Vol 3, Iss 1, Pp 1-

2022 Volume 10

Abstract: Average microbial biomass loads in glacial melt water are similar despite different environmental settings allowing for estimation of regional carbon export from melting glacier surfaces, according to direct observations at eight northern hemisphere ... ...

Abstract	Average microbial biomass loads in glacial melt water are similar despite different environmental settings allowing for estimation of regional carbon export from melting glacier surfaces, according to direct observations at eight northern hemisphere glaciers and two Greenland Ice Sheet sites.
Keywords	Geology ; QE1-996.5 ; Environmental sciences ; GE1-350
Language	English
Publishing date	2022-11-01T00:00:00Z
Publisher	Nature Portfolio
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Treatment of subperiosteal abscesses in children: is drainage of the intramedullary canal required?

Montgomery, Corey O / Porter, Austin / Sachleben, Brant / Suva, Larry J / Rabenhorst, Brian

Journal of pediatric orthopedics. Part B

2017 Volume 26, Issue 6, Page(s) 497–500

Abstract: Acute osteomyelitis can be successfully treated with antibiotics alone. Surgery is utilized after failure of antibiotic treatment or if an abscess is present. Limited evidence exists with regard to whether intramedullary drainage is required in addition ... ...

Abstract	Acute osteomyelitis can be successfully treated with antibiotics alone. Surgery is utilized after failure of antibiotic treatment or if an abscess is present. Limited evidence exists with regard to whether intramedullary drainage is required in addition to the drainage of the subperiosteal abscess. We reviewed our 9-year experience of treating subperiosteal abscesses identifying 68 patients. Thirty patients underwent both intramedullary and abscess drainage, whereas 38 patients underwent drainage of the abscess alone at the initial procedure. Our analysis demonstrated a statistical significance (P=0.012) and odds ratio of 6.46 in favor of an intramedullary drainage to decrease risk for need for repeat surgical treatment.
Language	English
Publishing date	2017-11
Publishing country	United States
Document type	Journal Article
ISSN	1473-5865
ISSN (online)	1473-5865
DOI	10.1097/BPB.0000000000000283
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Supervised Learning Classifiers for Electrical Impedance-based Bladder State Detection

Eoghan Dunne / Adam Santorelli / Brian McGinley / Geraldine Leader / Martin O’Halloran / Emily Porter

Scientific Reports, Vol 8, Iss 1, Pp 1-

2018 Volume 12

Abstract: Abstract Urinary Incontinence affects over 200 million people worldwide, severely impacting the quality of life of individuals. Bladder state detection technology has the potential to improve the lives of people with urinary incontinence by alerting the ... ...

Abstract	Abstract Urinary Incontinence affects over 200 million people worldwide, severely impacting the quality of life of individuals. Bladder state detection technology has the potential to improve the lives of people with urinary incontinence by alerting the user before voiding occurs. To this end, the objective of this study is to investigate the feasibility of using supervised machine learning classifiers to determine the bladder state of ‘full’ or ‘not full’ from electrical impedance measurements. Electrical impedance data was obtained from computational models and a realistic experimental pelvic phantom. Multiple datasets with increasing complexity were formed for varying noise levels in simulation. 10-Fold testing was performed on each dataset to classify ‘full’ and ‘not full’ bladder states, including phantom measurement data. Support vector machines and k-Nearest-Neighbours classifiers were compared in terms of accuracy, sensitivity, and specificity. The minimum and maximum accuracies across all datasets were 73.16% and 100%, respectively. Factors that contributed most to misclassification were the noise level and bladder volumes near the threshold of ‘full’ or ‘not full’. This paper represents the first study to use machine learning for bladder state detection with electrical impedance measurements. The results show promise for impedance-based bladder state detection to support those living with urinary incontinence.
Keywords	Medicine ; R ; Science ; Q
Subject code	006
Language	English
Publishing date	2018-03-01T00:00:00Z
Publisher	Nature Publishing Group
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Dynamics of T-Lymphocyte Activation Related to Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in Persons With Advanced HIV.

Tibúrcio, Rafael / Barreto-Duarte, Beatriz / Naredren, Gopolan / Queiroz, Artur T L / Anbalagan, Selvaraj / Nayak, Kaustuv / Ravichandran, Narayanan / Subramani, Rajasekaran / Antonelli, Lis R V / Satagopan, Kumar / Anbalagan, Komathi / Porter, Brian O / Sher, Alan / Swaminathan, Soumya / Sereti, Irini / Andrade, Bruno B

Frontiers in immunology

2021 Volume 12, Page(s) 757843

Abstract: Most persons living with HIV (PLWH) experience a significant restoration of their immunity associated with successful inhibition of viral replication after antiretroviral therapy (ART) initiation. Nevertheless, with the robust quantitative and ... ...

Abstract	Most persons living with HIV (PLWH) experience a significant restoration of their immunity associated with successful inhibition of viral replication after antiretroviral therapy (ART) initiation. Nevertheless, with the robust quantitative and qualitative restoration of CD4
MeSH term(s)	Acquired Immunodeficiency Syndrome/complications ; Acquired Immunodeficiency Syndrome/drug therapy ; Acquired Immunodeficiency Syndrome/immunology ; Anti-HIV Agents/pharmacology ; Anti-HIV Agents/therapeutic use ; Biomarkers ; CD4-CD8 Ratio ; CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/immunology ; Cytotoxicity, Immunologic ; Humans ; Immune Reconstitution Inflammatory Syndrome/blood ; Immune Reconstitution Inflammatory Syndrome/etiology ; Immune Reconstitution Inflammatory Syndrome/immunology ; Immunophenotyping ; Lymphocyte Activation ; Lymphopenia/etiology ; Lymphopenia/immunology ; Mycobacterium tuberculosis/immunology ; Observational Studies as Topic/statistics & numerical data ; Randomized Controlled Trials as Topic/statistics & numerical data ; Retrospective Studies ; T-Lymphocyte Subsets/immunology ; Tuberculosis/complications ; Tuberculosis/immunology
Chemical Substances	Anti-HIV Agents ; Biomarkers
Language	English
Publishing date	2021-10-07
Publishing country	Switzerland
Document type	Comparative Study ; Journal Article ; Research Support, N.I.H., Intramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2021.757843
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT.

Braun, Jürgen / Blanco, Ricardo / Marzo-Ortega, Helena / Gensler, Lianne S / van den Bosch, Filip / Hall, Stephen / Kameda, Hideto / Poddubnyy, Denis / van de Sande, Marleen / Wiksten, Anna S / Porter, Brian O / Shete, Abhijit / Richards, Hanno B / Haemmerle, Sibylle / Deodhar, Atul

Arthritis research & therapy

2021 Volume 23, Issue 1, Page(s) 231

Abstract: Background: To investigate the efficacy of secukinumab in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) grouped by disease activity as assessed by C-reactive protein (CRP) levels and/or magnetic resonance imaging (MRI) scores, ...

Abstract	Background: To investigate the efficacy of secukinumab in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) grouped by disease activity as assessed by C-reactive protein (CRP) levels and/or magnetic resonance imaging (MRI) scores, human leukocyte antigen (HLA)-B27 status, and sex. Methods: The phase III PREVENT study randomized (1:1:1) 555 patients to receive subcutaneous secukinumab 150 mg with (LD) or without (NL) loading dose or placebo weekly, followed by every 4 weeks starting at week 4. Here, we report the results of a post hoc analysis reporting the efficacy outcomes (pooled secukinumab) to 16 weeks by CRP, MRI, HLA-B27, and sex. Results: Efficacy differences between the secukinumab and the placebo groups were highest in the CRP+, MRI+, HLA-B27+, and male subgroups, particularly for Ankylosing Spondylitis Disease Activity Score-CRP inactive disease and Assessment of SpondyloArthritis international Society (ASAS) partial remission outcomes. ASAS40 response rates in the CRP+/MRI+ subgroup was 52.3% (secukinumab) versus 21.8% (placebo; P < 0.0001) at week 16. ASAS40 response rates (secukinumab versus placebo) were 43.9% versus 32.6% in HLA-B27+, 32.7% versus 16.4% in HLA-B27- subgroups, 51.2% versus 30.8% in male, and 31.7% versus 25.3% in female patients, respectively. Conclusions: Secukinumab improved the signs and symptoms of nr-axSpA across patients grouped by CRP (+/-) and/or MRI (+/-) status, HLA-B27 (+/-) status, and sex. The highest treatment differences between secukinumab and placebo were observed in patients with both elevated CRP and evidence of sacroiliitis on MRI. Treatment difference was minimal between HLA-B27 (+) and (-) subgroups. Male patients had higher relative responses than female patients. Trial registration: ClinicalTrials.gov , NCT02696031 . Registered on 02 March 2016.
MeSH term(s)	Antibodies, Monoclonal, Humanized ; Female ; HLA-B27 Antigen ; Humans ; Male ; Spondylarthritis/diagnostic imaging ; Spondylarthritis/drug therapy ; Spondylitis, Ankylosing/diagnostic imaging ; Spondylitis, Ankylosing/drug therapy ; Treatment Outcome
Chemical Substances	Antibodies, Monoclonal, Humanized ; HLA-B27 Antigen ; secukinumab (DLG4EML025)
Language	English
Publishing date	2021-09-04
Publishing country	England
Document type	Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	2107602-9
ISSN	1478-6362 ; 1478-6354
ISSN (online)	1478-6362
ISSN	1478-6354
DOI	10.1186/s13075-021-02613-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5490: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.

Pavelka, Karel / Kivitz, Alan J / Dokoupilova, Eva / Blanco, Ricardo / Maradiaga, Marco / Tahir, Hasan / Wang, Yi / Porter, Brian O / Stefanska, Anna / Richards, Hanno B / Rohrer, Susanne

ACR open rheumatology

2020 Volume 2, Issue 2, Page(s) 119–127

Abstract: Objective: Secukinumab 150 mg has demonstrated significant improvement in signs and symptoms of ankylosing spondylitis (AS), with response rates sustained for up to 5 years. Here, we report end-of-study 3-year efficacy and safety results of secukinumab ... ...

Abstract	Objective: Secukinumab 150 mg has demonstrated significant improvement in signs and symptoms of ankylosing spondylitis (AS), with response rates sustained for up to 5 years. Here, we report end-of-study 3-year efficacy and safety results of secukinumab 150 and 300 mg from the MEASURE 3 study. Methods: A total of 226 patients was randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous (s.c.) secukinumab 300/150 mg every 4 weeks or a matched placebo. At week 16, placebo patients were re-randomized to s.c. secukinumab 300/150 mg. Analysis at week 156 included patients initially randomized to secukinumab and those who switched from placebo to secukinumab at week 16 (any secukinumab 300/150 mg). Outcome measures at week 156 included Assessment of Spondyloarthritis International Society (ASAS) 20/40, Bath Ankylosing Spondylitis Disease Activity Index, ASAS partial remission (PR), ASAS 5/6, and Ankylosing Spondylitis Disease Activity Score-C-reactive protein inactive disease. Results: The retention rates from weeks 16 to 156 were 80.5% and 80.9% in secukinumab 300 and 150 mg, respectively. ASAS 20/40 response rates at week 156 were 75.0%/56.5% and 68.2%/47.7% for secukinumab 300 and 150 mg, respectively. At week 156, response rates on more stringent clinical end points (eg, ASAS 40, ASAS-PR) were higher with the 300-mg dose, particularly in tumor necrosis factor (TNF)-inadequate responder (IR) patients. No new safety findings were observed. Conclusion: Secukinumab (300 and 150 mg) provided sustained improvements through 3 years in the signs and symptoms of active AS. Improvements with secukinumab 300 mg were numerically higher compared with the 150-mg dose for some higher hurdle end points and in TNF-IR patients. The safety profile of secukinumab was consistent with previous reports.
Language	English
Publishing date	2020-01-20
Publishing country	United States
Document type	Journal Article
ISSN	2578-5745
ISSN (online)	2578-5745
DOI	10.1002/acr2.11102
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: An exploration of the interactive effects of leader trait goal orientation and goal content in teams

Porter, Christopher O. L. H / Darr, Wendy / Franklin, Douglas A / Swider, Brian W / Yu, Race Chien-Feng

The leadership quarterly : LQ ; an international journal of political, social and behavioral science Vol. 27, No. 1 , p. 34-50

2016 Volume 27, Issue 1, Page(s) 34–50

Author's details	Christopher O.L.H. Porter, Douglas A. Franklin, Brian W. Swider, Race Chien-Feng Yu
Keywords	Leadership ; Trait goal orientation ; Learning goals ; Performance goals ; Teams
Language	English
Publisher	Elsevier
Publishing place	Amsterdam
Document type	Article
ZDB-ID	1121641-4 ; 2019945-4
ISSN	1048-9843
ISSN	1048-9843
Database	ECONomics Information System

Order via subito

Article ; Online: Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study.

Deodhar, Atul / Blanco, Ricardo / Dokoupilová, Eva / Hall, Stephen / Kameda, Hideto / Kivitz, Alan J / Poddubnyy, Denis / van de Sande, Marleen / Wiksten, Anna S / Porter, Brian O / Richards, Hanno B / Haemmerle, Sibylle / Braun, Jürgen

Arthritis & rheumatology (Hoboken, N.J.)

2020 Volume 73, Issue 1, Page(s) 110–120

Abstract: Objective: To report the primary (1-year) results from PREVENT, the first phase III study evaluating secukinumab in patients with active nonradiographic axial spondyloarthritis (SpA).: Methods: A total of 555 patients were randomized (1:1:1) to ... ...

Abstract	Objective: To report the primary (1-year) results from PREVENT, the first phase III study evaluating secukinumab in patients with active nonradiographic axial spondyloarthritis (SpA). Methods: A total of 555 patients were randomized (1:1:1) to receive subcutaneous secukinumab 150 mg with a loading dose (loading dose [LD] group), secukinumab 150 mg without a loading dose (non-loading dose [NL] group), or placebo weekly and then every 4 weeks starting at week 4. The NL group received placebo at weeks 1, 2, and 3 to maintain blinding. Switch to open-label secukinumab or standard of care was permitted after week 20. The study had 2 independent analysis plans, per European Union and non-US (plan A; week 16) and US (plan B; week 52) regulatory requirements. The primary end point was 40% improvement in disease activity according to the Assessment of SpondyloArthritis international Society (ASAS40) criteria at week 16 (in the LD group) and at week 52 (in the NL group) in tumor necrosis factor inhibitor (TNFi)-naive patients. Safety analyses included all patients who received ≥1 dose of study treatment. Results: Overall, 481 patients completed 52 weeks of treatment, including 84.3% (156 of 185) in the LD group, 89.7% (165 of 184) in the NL group, and 86.0% (160 of 186) in the placebo group. The proportion of patients who switched to open-label or standard of care between weeks 20 and 48 was 50.8% in the LD group, 47.3% in the NL group, and 64.0% in the placebo group. Both primary and all secondary end points were met at week 16. The proportion of TNFi-naive patients who met ASAS40 was significantly higher for LD at week 16 (41.5%) and NL at week 52 (39.8%) versus placebo (29.2% at week 16 and 19.9% at week 52; both P < 0.05). No new safety findings were reported. Conclusion: Our findings indicate that secukinumab 150 mg provides significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Safety was consistent with previous reports.
MeSH term(s)	Adult ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antirheumatic Agents/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Spondylarthropathies/drug therapy ; Treatment Outcome
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antirheumatic Agents ; secukinumab (DLG4EML025)
Language	English
Publishing date	2020-11-24
Publishing country	United States
Document type	Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	2756371-6
ISSN	2326-5205 ; 2326-5191
ISSN (online)	2326-5205
ISSN	2326-5191
DOI	10.1002/art.41477
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 24: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito